Xilio Therapeutics, Inc.
NASDAQ:XLO
Overview | Financials
Company Name | Xilio Therapeutics, Inc. |
Symbol | XLO |
Currency | USD |
Price | 1.11 |
Market Cap | 48,793,461 |
Dividend Yield | 0% |
52-week-range | 0.5 - 1.93 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Rene Russo BCPS, Pharm.D, Pharm.D. |
Website | https://www.xiliotx.com |
An error occurred while fetching data.
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD